3RD Annual NYC Hep C Task Force Presentation
The Future of Hep C Treatment: A glimpse of the pharmaceutical pipeline and current treatment access advocacy
Tracy Swan, Treatment Action Group (TAG) firstname.lastname@example.org
Wednesday, Sept. 23rd (3 – 5 PM)
In attendance, see below
View presentation here : The Future of Hep C Treatment
Recent Publications co-authored by Tracy Swan
- 2015 HIV, HCV & TB Pipeline Report. Treatment Action Group. New Drugs, New Strategies: Conquering Hepatitis C with Direct-Acting Antivirals.
- Excluding People Who Use Drugs or Alcohol from Access to Hep C Treatment – Is This Fair, Given the Available Data? Journal of Hepatology, August 2015. This article examines Hep C treatment restrictions to assess whether they meet evidence-based medical and public health criteria, and whether they satisfy the principle of justice.
- Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy, 2015.
- Human rights and access to hepatitis C treatment for people who inject drugs. Int J Drug Policy, 2015.
- The promise of treatment as prevention for hepatitis C: Meeting the needs of people who inject drugs? Int J Drug Policy, 2015.
- Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. Ann Intern Med, 2015.
- Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries. Int J Drug Policy. 2015
- A path to eradication of hepatitis C in low- and middle-income countries. Antiviral Res, 2015.
- Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings. J Hepatol, 2014.
- Accelerating drug development through collaboration: the Hepatitis C Drug Development Advisory Group. Clin Pharmacol Ther. 2014
Paul Bolter, Health Educator, American Liver Foundation, email@example.com
Marie Bresnahan, Project Director, DOHMH, firstname.lastname@example.org
Fidel Bu Contreras, Program Director, Betances, email@example.com
Rodney Butler, Harm Reduction Coordinator, Harlem United, firstname.lastname@example.org
Margarita Cabral, Administrative Staff Analyst, NACC/NYCHA, email@example.com
Daniel Calder, Capacity Building Coordinator, DOHMH, firstname.lastname@example.org
Cinthia Castro, Patient Navigator, Harlem United, email@example.com
Jay Cowan, Medical Doctor, Corizon Health, Jay.Cowan@CorizonNYC.com
Ryan Duerme, Program Planner, Communicable Disease, DOHMH, firstname.lastname@example.org
Ian Heywood, Field Coordinator, Harlem United, email@example.com
Darrel Isaac, Field Coordinator, Harlem United, firstname.lastname@example.org
Nirah Johnson, LMSW, DOHMH, email@example.com
Umaima Khatun, Program Intern, DOHMH, firstname.lastname@example.org
Andrea King, City Research Scientist, DOHMH, email@example.com
Julie Lazaroff, Unit Chief, Perinatal Hep B, DOHMH Perinatal Hep Micaela Linder, Health Policy Research/Educator, The Fortune Society, firstname.lastname@example.org
Ed Manchess, Director, Harm Reduction Services, Boom Health, email@example.com
Miranda Moore, CSTE Fellow, Communicable Diseases, DOHMH, firstname.lastname@example.org
Jan Carl Park, Director, Health & Human Services Planning Council, DOHMH, email@example.com
Vinh Pham, MD, Bellevue HHC, firstname.lastname@example.org
Nina Rothschild, HIV Health and Human Services Planning Council of New York, DOHMH, email@example.com
Emily Wilkelstein, Cross Systems Program Specialist, DOHMH, firstname.lastname@example.org
Darryl Wong, Community Organizer, DOHMH HIV Planning Council, email@example.com
Eman Bassily, Public Health Advisor, DOHMH, firstname.lastname@example.org
Diana Diaz-Munoz, Program Intern, DOHMH, email@example.com
Brooke Wyatt, Mount Sinai Project INSPIRE Program Director, Montifiore , firstname.lastname@example.org
Tags: Hep C Task Force Committee